Evidence map›Paper›PMID 30514230›Full record

ArticleBMC cancer2018

EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.

Li Li, Yulun Huang, Yuge Gao, Tengfei Shi, Yunyun Xu, Huini Li, Marko Hyytiäinen, Jorma Keski-Oja, Qiuying Jiang, Yizhou Hu and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Crosstalk in Skin: Loss of Desmoglein 1 in Keratinocytes Inhibits BRAFThe Journal of investigative dermatology · 2025
    Article
  3. Review
  4. Dangerous liaisons: Loss of keratinocyte control over melanocytes in melanomagenesis.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  5. Research progress of the netrins and their receptors in cancer.Journal of cellular and molecular medicine · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Paradoxical Role of Cellular Senescence in Cancer.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Li LiDepartment of Oncology, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China.
Yulun HuangDepartment of Neurosurgery and Brain and Nerve Research Laboratory, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yuge GaoDepartment of Oncology, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China.
Tengfei ShiDepartment of Oncology, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China.
Yunyun XuInstitute of Pediatrics, Children's Hospital of Soochow University, Suzhou, China.
Huini LiDepartments of Virology and Pathology, Faculty of Medicine, the Haartman Institute, Translational Cancer Biology Research Program and Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Marko HyytiäinenDepartments of Virology and Pathology, Faculty of Medicine, the Haartman Institute, Translational Cancer Biology Research Program and Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Jorma Keski-OjaDepartments of Virology and Pathology, Faculty of Medicine, the Haartman Institute, Translational Cancer Biology Research Program and Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Qiuying JiangDepartment of Oncology, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China. jiangqiuying@medmail.com.cn.
Yizhou HuDepartments of Virology and Pathology, Faculty of Medicine, the Haartman Institute, Translational Cancer Biology Research Program and Helsinki University Hospital, University of Helsinki, Helsinki, Finland. yizhou.hu@ki.se.ORCID http://orcid.org/0000-0002-2635-0258
Zhimin DuDepartment of pharmacy, the Second Clinical College, Harbin Medical University, Harbin, People's Republic of China. dzm1956@126.com.
Harbin Medical University · CNUniversity of Helsinki · FISoochow University · CN

Funding

China Postdoctoral Science Foundation 2015M571439National Natural Science Foundation of China 31500718National Natural Science Foundation of China 81702464
6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of GBM cells to TMZ is affected by many factors. And, several clinic trials, including co-administration of TMZ with other drugs, have failed in successful treatment of GBM. We have previously reported that Netrin-4 (NTN4), a laminin-like axon guidance protein, plays a protective role in GBM cell senescence upon TMZ-triggered DNA damage. However, the master regulator of NTN4 needs further elucidation. Epidermal growth factor/Epidermal growth factor receptor (EGF/EGFR) can modulate the expression of various extracellular matrix related molecules, and prevent DNA damage in GBM cells. In this study, we investigated the relationship between EGF/EGFR signaling and NTN4, and explored their effect on therapeutic efficacy in GBM cells upon TMZ treatment.

methodsCo-expression analysis were performed by using the RNA sequencing data from NIH 934 cell lines and from single cell RNA sequencing data of GBM tumor. The co-expressing genes were used for GO enrichment and signaling pathway enrichment. mRNA expression of the target genes were quantified by qPCR, and cell senescence were investigated by Senescence-Associated Beta-Galactosidase Staining. Protein phosphorylation were observed and analyzed by immunoblotting. The RNA sequencing data and clinical information of TMZ treated patients were extracted from TCGA-glioblastoma project, and then used for Kaplan-Meier survival analysis.

resultsAnalysis of RNA sequencing data revealed a potential co-expression relationship between NTN4 and EGFR. GO enrichment of EGFR-correlated genes indicated that EGFR regulates GBM cells in a manner similar to that in central nervous system development and neural cell differentiation. Pathway analysis suggested that EGFR and its related genes contribute to cell adhesion, extracellular matrix (ECM) organization and caspase related signaling. We also show that EGF stimulates NTN4 expression in GBM cells and cooperates with NTN4 to attenuate GBM cell senescence induced by DNA damage, possibly via AKT and ERK. Clinical analysis showed that co-expression of EGFR and NTN4 significantly predicts poor survival in TMZ-treated GBM patients.

conclusionsThis study indicates that EGF/EGFR regulates and cooperates with NTN4 in DNA damage resistance in GBM. Therefore, our findings provide a potential therapeutic target for GBM.

Indexed as

Brain NeoplasmsCell Line, TumorCellular SenescenceDNA DamageEpidermal Growth FactorErbB ReceptorsGlioblastomaHumansNetrinsUp-RegulationEGFR protein, humanEpidermal Growth FactorErbB ReceptorsNetrinsNTN4 protein, humanCell senescenceEpidermal growth factorGlioblastomaNetrin-4

Identifiers

PMID30514230
PMCPMC6280426
OpenAlexW2903441014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.